Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ïåäèàòðèÿ > Âàêöèíîïðîôèëàêòèêà

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #61  
Ñòàðûé 02.01.2006, 23:57
Àâàòàð äëÿ Aminazinka
Aminazinka Aminazinka âíå ôîðóìà
Ìîë÷àëèâîå ïðèâèäåíèå
      
 
Ðåãèñòðàöèÿ: 25.12.2003
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 19,908
Ïîáëàãîäàðèëè 620 ðàç(à) çà 557 ñîîáùåíèé
Aminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò skeptic
Ñïàñèáî, ëþáåçíàÿ Aminazinka, çà Âàøå òðîãàòåëüíîå "Îñòàíüòåñü". Íî, ïî÷åìó çàêðûòûé. Ìåíÿ è, óâåðåí, Âàñ òóäà ïóñêàþò.
Âèçèò ä-ðà À.Êîòîêà ñþäà èëè êóäà áû òî íè áûëî âîâñå íå îáÿçàòåëåí. Ýòî íà åãî ñàéòå âñå ãîâîðÿùèå òî è äåëî, óñòðåìèâ âçîðû ê íåáó, âîñêëèöàþò: "Àëåêñàíäð... Àëåêñàíäð" è åù¸ ÁÈ...ÁÈ". Çàõî÷åò îí èëè íåò - ó ìåíÿ óæå åñòü ÁÈ (äðóã-ãîìåîïàò ïîäàðèë). Òàê ÷òî, ïðèõîäèòå.
Íó ìíå äî Âàñ äàëåêîâàòî... Íî âñå-òàêè òóò - íå ñîâñåì "òàì". Çäåñü íàñ (òî÷íåå Âàñ) ÷èòàþò íåâðà÷è (ïðåäïîëàãàåòñÿ, ÷òî íà Ñîëüâåå ôîðóì òîëüêî äëÿ âðà÷åé), à âåäü èìåííî èì ïðèõîäèòñÿ âûäåðæèâàòü óäàðû "ñòèõèè". Íàì ñïîðèòü î ïðèâèâêàõ íå ïðèäåòñÿ, íî ïðîòèâîäåéñòâîâàòü ìðàêîáåñèþ íàäî îáÿçàòåëüíî. Ïîýòîìó íà ìîé âçãëÿä âàæíî, ÷òîáû ïîèñêîâèêè ëîâèëè è ýòè ÎÒÊÐÛÒÛÅ îáñóæäåíèÿ.
Ïðî âèçèòû. Ìàññèðîâàííûå "ïîñåùåíèÿ" òóò ïåðèîäè÷åñêè ñëó÷àþòñÿ. Ñ òåì æå çàêàòûâàíèåì ãëàç è ðèòóàëüíûìè òàíöàìè. È îæèäàþòñÿ åùå. Ñ òåì æå ñàìûì ðàñ÷åòîì - íàø ôîðóì õîðîøî ïîñåùàåòñÿ. È ñêàçàííîå çäåñü èìååò âåñ. Íàì ïðåæäå íå óäàâàëîñü äîñòàòî÷íî õîðîøî âûãëÿäåòü â äèñêóññèÿõ ñ "äåñàíòíèêàìè", íî ó ìåíÿ åñòü íàäåæäà, ÷òî òåïåðü ìû ãîòîâû, áëàãîäàðÿ Âàì â òîì ÷èñëå.
__________________
Lead, follow, or get out of the way. — Thomas Paine
Îòâåòèòü ñ öèòèðîâàíèåì
  #62  
Ñòàðûé 05.01.2006, 21:48
KAI KAI âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
 
Ðåãèñòðàöèÿ: 24.10.2005
Ãîðîä: ÌÎÑÊÂÀ
Ñîîáùåíèé: 22
KAI
Óâàæàåìûé Àëåêñàíäð Íàóìîâè÷!
ß íå ìîãó îòâåòèòü íà Âàøå ïèñüìî (ïåðñîíàëüíîå ñîîáùåíèå), ò.ê. Âàø ïî÷òîâûé ÿùèê ïåðåïîëíåí.
Ñ óâàæåíèåì
Îòâåòèòü ñ öèòèðîâàíèåì
  #63  
Ñòàðûé 13.02.2006, 12:27
AlexGold AlexGold âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.12.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,570
Ïîáëàãîäàðèëè 584 ðàç(à) çà 482 ñîîáùåíèé
AlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íåäàâíèé îáçîð â äîïîëíåíèå ê îñíîâíîé òåìå.

Vaccine 22 (2004) 3375-3385

No epidemiological evidence for infant vaccinations to cause allergic disease

Koppen S, de Groot R, Neijens HJ, Nagelkerke N, van Eden W, Rümke HC

Context: The prevalence of allergic diseases has increased considerably over the last decades. The hygiene hypothesis has emerged, linking reduced microbial exposure and infections early in life with the development of allergic diseases. Especially some of currently available non-replicating infant vaccines are unlikely to mimic a natural infection-mediated immune response that protects against the development of allergic diseases. Moreover, several studies suggested infant vaccinations to increase the risk of allergic diseases.

Objective: To determine whether infant vaccinations increase the risk of developing allergic disease.

Data Sources: We searched MEDLINE from 1966 to March 2003 and bibliography lists from retrieved articles, and consulted experts in the field to identify all articles relating vaccination to allergy.

Study Selection and Data Extraction: We selected epidemiological studies with original data on the correlation between vaccination with diphtheria, pertussis, tetanus (DPT), measles, mumps, rubella (MMR) and Bacillus Calmette-Guérin (BCG) vaccine in infancy and the development of allergic diseases, and assessed their quality and validity.

Data Synthesis: Methodological design and quality varied considerably between the studies we reviewed. Many studies did not address possible confounders, such as the presence of lifestyle factors, leaving them prone to bias. The studies that offer the stronger evidence, including the only randomized controlled trial at issue published to date, indicate that the infant vaccinations we investigated do not increase the risk of developing allergic disease. Furthermore, BCG does not seem to reduce the risk of allergies.

Conclusions: The reviewed epidemiological evidence indicates that, although possibly not contributing to optimal stimulation of the immune system in infancy, current infant vaccines do not cause allergic diseases.
Îòâåòèòü ñ öèòèðîâàíèåì
  #64  
Ñòàðûé 27.02.2006, 11:20
AlexGold AlexGold âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.12.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,570
Ïîáëàãîäàðèëè 584 ðàç(à) çà 482 ñîîáùåíèé
AlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òîëüêî ÷òî îïóáëèêîâàííîå èññëåäîâàíèå íà çàäàííóþ òåìó.

Diphtheria, tetanus, pertussis, poliomyelitis vaccination and reported atopic disorders in 8–12-year-old children

Bernsen RMD et al. Vaccine 24 (2006) 2035-2042

Background: Evidence for the relationship between the diphtheria, tetanus, pertussis (DTP) vaccination and atopic disorders is inconclusive, because the available studies that constitute the evidence are liable to confounding by indication.

Study objective: To assess the relationship between diphtheria–tetanus-pertussis-(inactivated) poliomyelitis vaccination (DTP-IPV) in the first year of life and reported atopic disorders at primary school age.

Method: 1875 children attending Orthodox Reformed (Protestant) primary schools in the Netherlands returned questionnaires with data on vaccination status, atopic symptoms and lifetime atopic disorders (asthma, hay fever, eczema and food allergy), and possible confounders.

Results: The adjusted odds ratio of any atopic disorder (vaccinated/unvaccinated) was 1.00 (CI95%: 0.80–1.24). For asthma, hay fever, eczema and food allergy the results were respectively: 1.04 (CI95%: 0.76–1.42), 0.79 (CI95%: 0.55–1.12), 0.87 (CI95%: 0.66–1.14) and 1.13 (CI95%:0.71–1.81).

Conclusion: The DTP-IPV vaccination was not related to reported atopic disorders at primary school age.

 ðàçäåëå Discussion àâòîðû îòìå÷àþò: "This is the first study to compare vaccinated and unvaccinated children in a population where refraining from vaccinations is unlikely to be health-related. Moreover, the two groups had the same religious background, lived in the same area and attended the same schools. Possible differences were extensively surveyed and controlled for in the analyses. This situation is second best after a randomized controlled trial, which would not be feasible for ethical reasons".

Æåëàþùèì ìîãó ïðèñëàòü ïîëíûé òåêñò ñòàòüè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #65  
Ñòàðûé 27.03.2006, 14:06
Îéëÿëÿ Îéëÿëÿ âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 07.04.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 54
Îéëÿëÿ *
Âîïðîñ â òåìó. ß-àëëåðãèê+áð.àñòìà. Ìåíÿ íå âàêöèíèðîâàëè âîîáùå íè îò ÷åãî. Îò ïîëèîìåëèòà ïûòàëèñü â ðîääîìå- áûë ïðèñòóï. Áðàòà âàêöèíèðîâàëè, ó íåãî åùå ñèëüíîâûðàæåííûé ïîëëèíîç áûë, ïîêà íå ïðîëå÷èëñÿ ìèêðîäîçàìè àëëåðãåíîâ.
Òàê êàê ÿ âîîáùå íå âàêöèíèðîâàëàñü,è òàê êàê ÿ áû õîòåëà èçìåíèòü ñèòóàöèþ ñîñâîèì èììóíèòåòîì â ëóòøóþ ñòîðîíó, ìíå ðåêîìåíäóþò ÀÊÄÑ. Ðåêîìåíäóåò àëëåðãîëîã.
Äåëàòü?
âîîáùå õîòåëîñü áû êàê-òî íàëàäèòü âîïðîñ ñ âàêèöèíàöèåé, òàê êàê ðîæó ðåáåíêà è áóäó ñ íèì áîëåò ñâèíêàìè...
Îòâåòèòü ñ öèòèðîâàíèåì
  #66  
Ñòàðûé 27.03.2006, 18:59
Àâàòàð äëÿ Dr.Nathalie
Dr.Nathalie Dr.Nathalie âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.08.2003
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 24,881
Ïîáëàãîäàðèëè 5,532 ðàç(à) çà 4,217 ñîîáùåíèé
Dr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Îéëÿëÿ!
Îò ïîëèîìèåëèòà íå âàêöèíèðóþò â ðîääîìå.
Ó ìëàäåíöåâ â ðàííåì íåîíàòàëüíîì ïåðèîäå íå áûâàåò "ïðèñòóïîâ" áðîíõèàëüíîé àñòìû.
È âîîáùå, ïðîñòèòå, íî Âàøå ñîîáùåíèå î÷åíü ñáèâ÷èâîå è ìàëî ïîíÿòíîå. Åñëè Âàñ íå çàòðóäíèò, ïîäóìàéòå, ÷òî Âû õîòèòå ñïðîñèòü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #67  
Ñòàðûé 28.03.2006, 13:21
Îéëÿëÿ Îéëÿëÿ âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 07.04.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 54
Îéëÿëÿ *
õîðîøî.
1) îò ïðèâèâîê ó ìåíÿ áûë ìåäîòâîä. Íå çíàþ ïî÷åìó. çäåñü íàïèñàëà ëèøü, òî ÷òî ìåíå ñêàçàëà ìàìà. Êîðî÷å, ÿ íå ïðèâèòà âîîáùå.
2) ó ìåíÿ áðîíõèàëüíàÿ àñòìà è àëëåðãèÿ íà ïî÷òè âñ¸. Íî æèâó ÿ äîñòàòî÷íî ïîëíîöåííîé æèçíüþ, äàæå ïîëèíîçà íåò âåñåííåãî. À âîò ó ìîåãî áðàòà î÷åíü ñèëüíûé ïîëèíîç. (Îí ìîé ðîäñòâåííèê, òàê ÷òî ïðåäïîëîãàþ, èìóííûå íàðóøåíèÿ ó íàñ ñõîäíûå). Åãî âàêöèíèðîâàëè. Îò ÷åãî íå çíàþ.
3) ÿ õî÷ó ïðèâèòüñÿ ïî 3 ïðè÷èíàì. 1) ïëàíèðóþ èìåòü ðåáåíêà, íå õîòåëîñü áû áîëåòü ñ íèì âñåìè äåòñêèìè áîëåçíÿìè.2) Õî÷ó ïðèâèòñÿ! òàê êàê íå õî÷ó áîëåòü!3) Ó ìåíÿ èìååòñÿ ðåöåäèâèðóþùèé ãåðïåñ òÿæåëîé ôîðìû, è ...(ýòî ëè÷íî ìîè óìîçàêëþ÷åíèÿ íå îñíîâàííûå íè íà ÷åì, íî ÿ èõ ñþäà âïèøó) åñòü ñëó÷àè â ìåäèöèíå êîãäà ïðèâèâàÿ îò äðóãèõ òèïîâ âèðóñîâ, èìóííàÿ ñèñåìà íà÷èíàëà àêòèâíî ôóíêöèîíèðîâàòü è "íîðìàëüíî" îòâå÷òü íà âèðóñ óæå èìåþùèéñÿ â îðãàíèçìå

Ñïðîñèòü õî÷ó èìåííî òî êàê çâó÷èò òåìà ýòîãî ôîðóìà. ÓÂÅËÈ×ÈÂÀÞÒ ËÈ ÄÅÒÑÊÈÅ ÏÐÈÂÈÂÊÈ ÐÈÑÊ ÐÀÇÂÈÒÈß ÏÎËÈÈÍÎÇÀ òåì áîëåå ó ìåíÿ - àëëåðãèêà.

Ìíå àëëåðãîëîã ïîñëå òîãî âñòóïëåíèÿ êîòîðîÿ ÿ çäåñü ïðèâåëà, äëÿ ðåøåíèÿ èìåííî ãåðïåòè÷åñêîé ïðîáëåìû ðåêîìåíäîâàë ÀÊÄÑ(òàê êàê òîì êàêèå-òî ñòåíêè êëåòîê), è ðåçóëüòàò îòâåòà èììóíîé ñèñòåìû ìîæíî ïî åãî ñëîâàì æäàòü òîëüêî îò ÀÊÄÑ( äð. ïîä.âàêöèí). ÍÎ ß ÁÎÞÑÜ ×ÒÎ ÏÎÑËÅ ÂÀÊÖÈÍÛ ìîé óìåðåííûé ïîëèíîç, ïðåâðàòèòüñÿ â ïîëèíîç òàêîé êàê ó áðàòà, ñ ïðèñòóïàìè êàæäûé äåíü....
Îòâåòèòü ñ öèòèðîâàíèåì
  #68  
Ñòàðûé 28.03.2006, 17:14
Àâàòàð äëÿ Dr.Nathalie
Dr.Nathalie Dr.Nathalie âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.08.2003
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 24,881
Ïîáëàãîäàðèëè 5,532 ðàç(à) çà 4,217 ñîîáùåíèé
Dr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Nathalie ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Îéëÿëÿ!
ß äóìàþ, ÷òî Âàì íàäî îáñóäèòü âîïðîñ î âàêöèíàöèè ñ âàøèì ïóëüìîíîëîãîì (âàêöèíàöèÿ "ïîä ïðèêðûòèåì" áàçèñíîé òåðàïèè, àíòèãèñòàìèííûõ ïðåïàðàòîâ). ×òî êàñàåòñÿ ñîáñòâåííî ðèñêà ðàçâèòèÿ ïîëëèíîçà, åñëè Âû âíèìàòåëüíî ïî÷èòàëè ïðåäûäóùèå ñòðàíèöû äàííîé òåìû, òî Âû îáðàòèëè âíèìàíèå íà òî, ÷òî â öåëîì ìû ñêëîíÿåìñÿ ê òîìó, ÷òî íåò, íå âûçûâàåò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #69  
Ñòàðûé 29.03.2006, 17:57
AlexGold AlexGold âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.12.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,570
Ïîáëàãîäàðèëè 584 ðàç(à) çà 482 ñîîáùåíèé
AlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Îéëÿëÿ
Ìíå àëëåðãîëîã ïîñëå òîãî âñòóïëåíèÿ êîòîðîÿ ÿ çäåñü ïðèâåëà, äëÿ ðåøåíèÿ èìåííî ãåðïåòè÷åñêîé ïðîáëåìû ðåêîìåíäîâàë ÀÊÄÑ(òàê êàê òîì êàêèå-òî ñòåíêè êëåòîê)
Êàêèå áû ñòåíêè êëåòîê íå áûëè â ÀÊÄÑ åå íåëüçÿ ïðèìåíÿòü ó âçðîñëûõ. Ñîãëàñíî èíñòðóêöèè, îíà ïðèìåíÿåòñÿ òîëüêî ó äåòåé äî 3-õ ëåò âêëþ÷èòåëüíî. Íà êàêîì îñíîâàíèè àëëåðãîëîã ïîðåêîìåíäîâàë ââåñòè âçðîñëîìó âàêöèíó ÀÊÄÑ ìíå ñîâåðøåííî íåïîíÿòíî.

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Nathalie îäîáðèë(à): !
Îòâåòèòü ñ öèòèðîâàíèåì
  #70  
Ñòàðûé 31.03.2006, 09:40
Îéëÿëÿ Îéëÿëÿ âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 07.04.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 54
Îéëÿëÿ *
Íà êàêîì îñíîâàíèè àëëåðãîëîã ïîðåêîìåíäîâàë ââåñòè âçðîñëîìó âàêöèíó ÀÊÄÑ ìíå ñîâåðøåííî íåïîíÿòíî.[/quote]


Íà òîì îñíîâàíèè, ÷òî â 26 ëåò íóæíî ðåâàêöèíèðîâàòüñÿ ÀÊÄÑ-îì :-))
Îòâåòèòü ñ öèòèðîâàíèåì
  #71  
Ñòàðûé 31.03.2006, 09:49
AlexGold AlexGold âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.12.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,570
Ïîáëàãîäàðèëè 584 ðàç(à) çà 482 ñîîáùåíèé
AlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
 26 ëåò ðåâàêöèíàöèÿ ïðîâîäèòñÿ íå âàêöèíîé ÀÊÄÑ, à âàêöèíîé ÀÄÑ-Ì. Êðîìå òîãî, îäíîêðàòíàÿ ðåâàêöèíàöèÿ ïðîâîäèòñÿ ðàíåå ïðèâèòûì. Ïîñêîëüêó Âû íå áûëè ïðèâèòû ñîâñåì, òî Âàì ñëåäóåò ïðîéòè êóðñ ïåðâè÷íîé âàêöèíàöèè ïðîòèâ äèôòåðèè è ñòîëáíÿêà, êîòîðûé äëÿ âçðîñëûõ ñîñòîèò èç äâóõ äîç âàêöèíû ÀÄÑ-Ì ñ èíòåðâàëîì 1,5-2 ìåñ. ñ ïîñëåäóþùåé ðåâàêöèíàöèåé ÷åðåç 6-9 ìåñ. ïîñëå âòîðîé äîçû. Âòîðàÿ ðåâàêöèíàöèÿ ÀÄÑ-Ì ïðîâîäèòñÿ ÷åðåç 5 ëåò ïîñëå ïåðâîé, çàòåì - ÷åðåç êàæäûå 10 ëåò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #72  
Ñòàðûé 12.01.2007, 17:51
AlexGold AlexGold âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.12.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,570
Ïîáëàãîäàðèëè 584 ðàç(à) çà 482 ñîîáùåíèé
AlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ðàñïðîñòðàíåííîñòü àñòìû è ñóììàðíîå ÷èñëî äîç ðåêîìåíäîâàííûõ ïðèâèâîê â ÑØÀ, 1980-2004 (ñì. ïðèêðåïëåííûé ãðàôèê)

Èñòî÷íèê: Enriquez R, Hartert T, and Persky V. Trends in asthma prevalence and recommended number of childhood immunizations are not parallel. Pediatrics 2007; 119:222-223
Èçîáðàæåíèÿ
Òèï ôàéëà: jpg Asthma prevalence and number of immunizations_USA, 1980-2004 .jpg (14.3 Êá, 196 ïðîñìîòðîâ)
Îòâåòèòü ñ öèòèðîâàíèåì
  #73  
Ñòàðûé 17.01.2007, 14:42
AlexGold AlexGold âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.12.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,570
Ïîáëàãîäàðèëè 584 ðàç(à) çà 482 ñîîáùåíèé
AlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âàêöèíàöèÿ ÁÖÆ ïðè ðîæäåíèè íå óâåëè÷èâàåò ðèñê ðàçâèòèÿ àëëåðãè÷åñêèõ çàáîëåâàíèé

Âàêöèíàöèÿ ÁÖÆ ïðè ðîæäåíèè è àòîïè÷åñêèå çàáîëåâàíèÿ â ãîìîãåííîé ïîïóëÿöèè èñïàíñêèõ øêîëüíèêîâ.

L. García-Marcos [a], M. Morales Suárez-Varela [b], I. Miner Canflanca [c], J. Batlles Garrido [d], A. Blanco Quirós [e], A. López-Silvarrey Varela [f], G. García Hernández [g], F. Guillén-Grima [h], C. González Díaz [i], I. Huerta González [j], A. Arnedo Pena [k], R. Busquets Monge [l]

a Cartagena Clinical and Research Unit and Department of Pediatrics, University of Murcia, Murcia,
b Public and Environmental Health Unit, Department of Preventive Medicine, University of Valencia, Valencia,
c Department of Pediatrics, Donostia Hospital, San Sebastián,
d Department of Pediatrics, Torrecárdenas Hospital, Almería,
e Department of Pediatrics, University of Valladolid, Valladolid,
f María José Jove Foundation, La Coruña,
g Pediatric Allergy and Pneumology Unit, 12 de Octubre Children's Hospital, Madrid,
h Department of Health Sciences, Public University of Navarra, Navarra,
i Department of Pediatrics, Basurto Hospital, Bilbao,
j Department of Public Health, Regional Health Authority, Asturias,
k Department of Epidemiology, Regional Health Authority, Castellón, and
l Department of Pediatrics, Hospital del Mar UAB, Barcelona, Spain

Ïðåäïîñûëêè ê èññëåäîâàíèþ. Ðîëü âàêöèíàöèè ÁÖÆ â ðàñïðîñòðàíåííîñòè àñòìû, àëëåðãè÷åñêîãî ðèíèòà è àòîïè÷åñêîãî äåðìàòèòà òî÷íî íå îïðåäåëåíà è ïî-âèäèìîìó çàâèñèò îò ýòíè÷åñêîé ïðèíàäëåæíîñòè. Äàííîå èññëåäîâàíèå ïðåäïðèíÿòî ñ öåëüþ ïðîàíàëèçèðîâàòü âçàèìîñâÿçü ìåæäó äàííîé âàêöèíàöèåé è ðàñïðîñòðàíåííîñòüþ óêàçàííûõ çàáîëåâàíèé â ãîìîãåííîé ïîïóëÿöèè èñïàíñêèõ øêîëüíèêîâ.

Ìåòîäû.  ÷åòûðåõ öåíòðàõ èññëåäîâàíèÿ, ðàñïîëîæåííûõ íà ñåâåðîàòëàíòè÷åñêîì ïîáåðåæüå Èñïàíèè, áûëè èñïîëüçîâàíû îñíîâíîé è äîïîëíèòåëüíûé âîïðîñíèêè Ìåæäóíàðîäíîãî Èññëåäîâàíèÿ Àñòìû è Àëëåðãè÷åñêèõ çàáîëåâàíèé ó Äåòåé (ISAAC).  Áèëüáàî, Ñàí-Ñåáàñòüÿíå è Àñòóðèè ïðåäóñìîòðåíà âàêöèíàöèÿ ÁÖÆ âñåõ äåòåé â ïåðâûå äíè æèçíè, òîãäà êàê â Ëà Êîðóíüå òàêàÿ ïðàêòèêà áûëà ïðåêðàùåíà 1989 ã. Çà èñêëþ÷åíèåì ïîñëåäíåãî ãîðîäà, îõâàò âàêöèíàöèåé áûë âûøå 90%. Áûëè èññëåäîâàíû äåòè â âîçðàñòå 6-7 ëåò, ïîñåùàþùèå øêîëó. Ïîñëåäíèå áûëè ñëó÷àéíûì îáðàçîì âûáðàíû â Àñòóðèè, â îñòàëüíûõ ãîðîäàõ èññëåäîâàíèå áûëî ïðîâåäåíî âî âñåõ øêîëàõ.

Ðåçóëüòàòû. Äîëÿ ïðèíÿâøèõ ó÷àñòèå â îïðîñå ñîñòàâèëà áîëåå 70%. Ïîñëå èñêëþ÷åíèÿ äåòåé, ðîäèâøèõñÿ íå â Èñïàíèè, ÷èñëî ïðèâèòûõ ó÷àñòíèêîâ èññëåäîâàíèÿ ñîñòàâèëî 6762 ÷åë., ÷èñëî íåïðèâèòûõ – 2828 ÷åë. Ïîñëå âûðàâíèâàíèÿ ãðóïï ïî ïîëó, âîçðàñòó, êóðåíèþ ìàòåðè èëè îòöà, èíòåíñèâíîñòè äâèæåíèÿ òðàíñïîðòà âáëèçè äîìà, íàëè÷èþ ñòàðøèõ èëè ìëàäøèõ áðàòüåâ/ñåñòåð, íàëè÷èþ êîøêè èëè ñîáàêè â äîìå â ïåðâûé ãîä æèçíè ðåáåíêà, îòíîñèòåëüíûé ðèñê ðàçâèòèÿ àñòìû, àëëåðãè÷åñêîãî ðèíèòà è àòîïè÷åñêîãî äåðìàòèòà ó ïðèâèòûõ ÁÖÆ ïî ñðàâíåíèþ ñ íåïðèâèòûìè äåòüìè ñîñòàâèë 0,87 (95% ÄÈ 0,76-1,00), 0,87 (95% ÄÈ 0,75-1,01) è 0,89 (95% ÄÈ 0,76-1,05) ñîîòâåòñòâåííî.

Âûâîäû. Âàêöèíàöèÿ ÁÖÆ ïðèâîäèò ê ñëàáîé, íî çíà÷èìîé çàùèòå â îòíîøåíèè ðàçâèòèÿ àñòìû è àëëåðãè÷åñêîãî ðèíèòà ó èñïàíñêèõ øêîëüíèêîâ.

International Archives of Allergy and Immunology 2005; 137:303-309

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #74  
Ñòàðûé 21.02.2007, 11:23
AlexGold AlexGold âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.12.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,570
Ïîáëàãîäàðèëè 584 ðàç(à) çà 482 ñîîáùåíèé
AlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âàêöèíàöèÿ ïðîòèâ äèôòåðèè, êîêëþøà, ïîëèîìèåëèòà, ñòîëáíÿêà, ãåìîôèëüíîé èíôåêöèè òèïà b è ðèñê âîçíèêíîâåíèÿ ýêçåìû èëè ïîâòîðÿþùèõñÿ ñèìïòîìîâ áðîíõîîáñòðóêöèè íà ïåðâîì ãîäó æèçíè: êîãîðòíîå èññëåäîâàíèå KOALA

Pediatrics 2007; 119:e367-e373

Ischa Kummeling, MSc [a], Carel Thijs, MD, PhD [a], Foekje Stelma, MD, PhD [b], Macheld Huber, MD [c], Piet A. van den Brandt, PhD [a] and Pieter C. Dagnelie, PhD [a]

[a] Department of Epidemiology, Maastricht University, Maastricht, Netherlands
[b] Department of Medical Microbiology, University Hospital of Maastricht, Maastricht, Netherlands
[c] Louis Bolk Institute, Driebergen, Netherlands

Öåëè èññëåäîâàíèÿ.  ïîñëåäíåå âðåìÿ âàêöèíàöèÿ, ïðîâîäÿùàÿñÿ íà ïåðâîì ãîäó æèçíè, îáñóæäàåòñÿ êàê ïîòåíöèàëüíàÿ ïðè÷èíà âîçíèêíîâåíèÿ ñèìïòîìîâ àòîïèè.  õîäå ïðîñïåêòèâíîãî èññëåäîâàíèÿ ìû èçó÷àëè ñíèæàåòñÿ ëè ðèñê ðàçâèòèÿ ýêçåìû èëè ïîâòîðÿþùèõñÿ ñèìïòîìîâ áðîíõîîáñòðóêöèè â ïåðâûé ãîä æèçíè ó äåòåé, êîòîðûå íå áûëè ïðèâèòû èëè áûëè ïðèâèòû íåïîëíîñòüþ â ïåðâûå 6 ìåñ. æèçíè.

Ìåòîäû. Èíôîðìàöèÿ î âàêöèíàöèè ïðîòèâ äèôòåðèè, êîêëþøà, ïîëèîìèåëèòà, ñòîëáíÿêà, ãåìîôèëüíîé èíôåêöèè òèïà b, à òàêæå î ñèìïòîìàõ ýêçåìû è ïîâòîðÿþùèõñÿ ñèìïòîìàõ áðîíõîîáñòðóêöèè áûëà ñîáðàíà ñ ïîìîùüþ íåñêîëüêèõ îïðîñîâ 2764 ñåìåé, ó÷àñòâóþùèõ â êîãîðòíîì èññëåäîâàíèè KOALA, ïðîâîäÿùåìñÿ â Ãîëëàíäèè. Ñòàíäàðòíûé ãðàôèê âàêöèíàöèè ïðåäóñìàòðèâàåò 3-êðàòíóþ âàêöèíàöèþ ïðîòèâ äèôòåðèè, êîêëþøà, ïîëèîìèåëèòà, ñòîëáíÿêà, ãåìîôèëüíîé èíôåêöèè òèïà b â ïåðâûå 6 ìåñ. æèçíè, ïåðâàÿ èç êîòîðûõ ïðîâîäèòñÿ â âîçðàñòå 1-3 ìåñ. Äåòè ñ ëþáûìè îòêëîíåíèÿìè îò óêàçàííîãî ãðàôèêà ðàññìàòðèâàëèñü êàê íåïîëíîñòüþ ïðèâèòûå. Êðèòåðèÿìè èñêëþ÷åíèÿ áûëà íåäîíîøåííîñòü (ìåíåå 37 íåäåëü ãåñòàöèè) è âðîæäåííûå íàðóøåíèÿ, ñâÿçàííûå ñ èììóíèòåòîì (òàêèõ êàê ñèíäðîì Äàóíà). Ñ öåëüþ ó÷åòà äîïîëíèòåëüíûõ ôàêòîðîâ, ñïîñîáíûõ ïîâëèÿòü íà èçó÷àåìûé ðåçóëüòàò, ïðèìåíÿëñÿ ìåòîä ìíîæåñòâåííîé ëîãèñòè÷åñêîé ðåãðåññèè.

Ðåçóëüòàòû.  òå÷åíèå ïåðâîãî ãîäà æèçíè çàáîëåâàåìîñòü ýêçåìîé ñîñòàâèëà 23% (584 èç 2537 äåòåé), ïîâòîðÿþùèåñÿ ñèìïòîìû áðîõîîáñòðóêöèè îòìå÷åíû ó 8,5% (203 èç 2402 äåòåé). Ê âîçðàñòó 6 ìåñ., 1969 (77%) èç 2545 äåòåé áûëè ïðèâèòû â ñîîòâåòñòâèè ñ ðåêîìåíäîâàííûì ãðàôèêîì, 393 (15%) áûëè ïðèâèòû íåïîëíîñòüþ, 182 (7%) áûëè ïîëíîñòüþ íåïðèâèòû. Ïî ñðàâíåíèþ ñ äåòüìè, ïðèâèòûìè ïî ñòàíäàðòíîìó ãðàôèêó, ðèñê ýêçåìû èëè ïîâòîðÿþùèõñÿ ñèìïòîìîâ áðîíõîîáñòðóêöèè ó íåïîëíîñòüþ ïðèâèòûõ äåòåé çíà÷èìî íå èçìåíÿëñÿ. Òàêîé æå ðåçóëüòàò ïîëó÷åí äëÿ ïîëíîñòüþ íåïðèâèòûõ äåòåé.

Ïîëíûé òåêñò ñòàòüè äîñòóïåí ïî àäðåñó: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #75  
Ñòàðûé 16.03.2007, 11:39
AlexGold AlexGold âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 09.12.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,570
Ïîáëàãîäàðèëè 584 ðàç(à) çà 482 ñîîáùåíèé
AlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexGold ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âàêöèíû, àíòèáèîòèêè è àëëåðãèÿ

Pharmacoepidemiol Drug Saf 2007; 16:275-278

John P. Mullooly PhD [1], Roberleigh Schuler MS [1], Michael Barrett MD [2] and Julie E. Maher PhD [1]

[1] Center for Health Research, Kaiser Permanente Northwest, USA
[2] Permanente Medical Group, Kaiser Permanente Northwest, USA

Öåëü èññëåäîâàíèÿ. Èñïîëüçîâàíèå âàêöèí è àíòèáèîòèêîâ â ðàííåì âîçðàñòå ìîæåò óâåëè÷èâàòü ðèñê ðàçâèòèÿ àòîïèè, çàùèùàÿ îðãàíèçì îò èíôåêöèîííûõ àãåíòîâ è ñíèæàÿ äëèòåëüíîñòü è òÿæåñòü òå÷åíèÿ èíôåêöèé (ãèãèåíè÷åñêàÿ ãèïîòåçà). Èõ èñïîëüçîâàíèå òàêæå ìîæåò ñäâèãàòü ðàçâèâàþùóþñÿ èììóííóþ ñèñòåìó â ñòîðîíó áîëüøåé ñêëîííîñòè ê àëëåðãè÷åñêîìó îòâåòó. Ìû èçó÷èëè ïîäîáíóþ âîçìîæíóþ âçàèìîñâÿçü ó äåòåé, íàáëþäàþùèõñÿ â àëëåðãîëîãè÷åñêîé êëèíèêå.

Ìåòîäû. Ìû ïðîâåëè èññëåäîâàíèå ïî ìåòîäó «ñëó÷àé-êîíòðîëü» ñðåäè íîâûõ ïàöèåíòîâ àëëåðãîëîãè÷åñêîé êëèíèêè â âîçðàñòå îò 6 äî 16 ëåò, êîòîðûì ïðîâîäèëîñü êîæíîå òåñòèðîâàíèå íà èíãàëÿöèîííûå àíòèãåíû â ïåðèîä 1987-2001 ãã. è êîòîðûå íàáëþäàëèñü â íàøåì ó÷ðåæäåíèè (Kaiser Permanente Northwest, KPNW) ñ ðîæäåíèÿ (n=1074). Ê ãðóïïå «ñëó÷àé», èìåþùåé àòîïèþ, áûëè îòíåñåíû äåòè, èìåâøèå ïîëîæèòåëüíûé êîæíûé òåñò õîòÿ áû íà îäèí èíãàëÿöèîííûé àëëåðãåí. Ê ãðóïïå «êîíòðîëü», íå èìåþùåé àòîïèè, áûëè îòíåñåíû äåòè ñ îòðèöàòåëüíûì êîæíûì òåñòîì íà âñå èíãàëÿöèîííûå àíòèãåíû. Èñïîëüçóÿ ëîãèñòè÷åñêèé ðåãðåññèîííûé àíàëèç, ìû îöåíèâàëè îòíîñèòåëüíûå ðèñêè èñïîëüçîâàíèÿ âàêöèí è àíòèáèîòèêîâ, à òàêæå âçàèìîñâÿçü ìåæäó ïðèìåíåíèåì âàêöèí è àíòèáèîòèêîâ â òå÷åíèå ïåðâûõ 2 ëåò æèçíè è ïîñëåäóþùåé ïîñòàíîâêîé íîâûõ äèàãíîçîâ àëëåðãè÷åñêèõ çàáîëåâàíèé.

Ðåçóëüòàòû. Íå îáíàðóæåíî çíà÷èìîé âçàèìîñâÿçè ìåæäó àòîïèåé è ÷èñëîì ââåäåííûõ â ïåðâûå 2 ãîäà æèçíè äîç âàêöèí è àíòèãåíîâ, à òàêæå ìåæäó àòîïèåé è ÷èñëîì ðàçëè÷íûõ ââåäåííûõ â ïåðâûå 2 ãîäà æèçíè àíòèãåíîâ. Ðèñê ðàçâèòèÿ àòîïèè íàõîäèëñÿ â îáðàòíîé çàâèñèìîñòè îò ÷èñëà ñëó÷àåâ íàçíà÷åíèÿ àíòèáèîòèêîâ. Çíà÷èìîé âçàèìîñâÿçè ñ ïîñòàíîâêîé íîâîãî äèàãíîçà àëëåðãè÷åñêîãî çàáîëåâàíèÿ ó äåòåé ñ àòîïèåé íå áûëî íàéäåíî íè ïî îäíîìó èç óêàçàííûõ ñðàâíåíèé.

Çàêëþ÷åíèå. Ðàçâèòèå àòîïèè, ïî-âèäèìîìó, íå ñâÿçàíî ñ èñïîëüçîâàíèåì âàêöèí â ðàííåì äåòñêîì âîçðàñòå. Áîëåå ÷àñòîå íàçíà÷åíèå àíòèáèîòêîâ (êîñâåííûé ïîêàçàòåëü ÷àñòîòû èíôåêöèé) â ðàííåì äåòñêîì âîçðàñòå, ïî-âèäèìîìó, çàùèùàåò îò àëëåðãè÷åñêîé ñåíñèòèçàöèè. Íè âàêöèíû, íè àíòèáèîòèêè íå èíäóöèðóþò â ïîñëåäóþùåì àëëåðãè÷åñêèå çàáîëåâàíèÿ ó äåòåé ñ àòîïèåé.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 04:00.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.